Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study

被引：0
|
作者：
Dent, S. [1 ]
Alder, L. [1 ]
Broadwater, G. [1 ]
Hyslop, T. [1 ]
Oeffinger, K. [1 ]
Khouri, M. [1 ]
Balu, S. [2 ]
Kimmick, G. [1 ]
机构：
[1] Duke Canc Inst, Cardiooncol, Durham, NC USA
[2] Novartis Pharmaceut, HEOR, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324P
引用
收藏
页码：S505 / S506
页数：2
相关论文
共 50 条
  • [41] Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2- metastatic breast cancer treated with a CDK4/6i in the first-line setting (vol 31, pg 6, 2025)
    Behan, E.
    Veenstra, D. L.
    Bansal, A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (02): : 226 - 226
  • [42] Phase la study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR+/HER2-advanced breast cancer
    Zhang, Jian
    Wang, Xiaojia
    Wang, Xian
    Hui, Aimin
    Wu, Zhuli
    Tian, Ling
    Xu, Changjiang
    Yang, Yuchen
    Zhang, Wenjing
    Hu, Xichun
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1549 - 1558
  • [43] Does HER2 Affect CDK4/6 Pathway Activity in Breast Cancer?
    Cui, Xiaoyan
    Sinclair, William
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 92 - 94
  • [44] Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer
    Zhang, Cui
    Zhou, Fulin
    Zou, Jiali
    Fang, Yanman
    Liu, Yuncong
    Li, Libo
    Hou, Jing
    Wang, Guanghui
    Wang, Hua
    Lai, Xiaolian
    Xie, Lu
    Jiang, Jia
    Yang, Can
    Huang, Yisidan
    Chen, Yingji
    Zhang, Hanqun
    Li, Yong
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [45] CDK4/6 inhibitors in advanced HR+/HER2-breast cancer - a multicenter real world data analysis
    Mueller, C.
    Kiver, V
    Solomayer, E-F
    Wagenpfeil, G.
    Neeb, C.
    Blohmer, J. U.
    Abramian, A., V
    Maass, N.
    Schuetz, F.
    Kolberg-Liedtke, C.
    Ralser, D. J.
    Rambow, A-C
    BREAST CARE, 2023, 18 (01) : 31 - 41
  • [46] Does HER2 Affect CDK4/6 Pathway Activity in Breast Cancer?
    Cui, Xiaoyan
    Sinclair, William
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 92 - 94
  • [47] A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2-advanced breast cancer
    Sanchez-Bayona, Rodrigo
    Alva, Manuel
    de Sa, Alfonso Lopez
    Gilarranz, Yolanda Jerez
    de Torre, Ana Sanchez
    Tolosa, Pablo
    de Luna, Alicia
    Lopez-Tarruella, Sara
    Lema, Laura
    Moreno, Fernando
    Echavarria, Isabel
    Madariaga, Ainhoa
    Benitez, Javier
    Herrero, Blanca
    Rey, Macarena
    Ortega, Justo
    Gamez, Salvador
    Modrego, Andrea
    Lozano, Rocio Martin
    Figuero-Perez, Luis
    Jimenez, Roberto
    Sevilla, Marta Gonzalez
    Gonzalez, Irene
    Beranek, Marianela Bringas
    de Toro, Maria
    Massarrah, Tatiana
    del Monte-Millan, Maria
    Pinardo, Marina
    Manso, Luis
    Bueno-Muino, Coralia
    Garcia-Saenz, Jose Angel
    Martin, Miguel
    Ciruelos, Eva
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study
    Wu, Yun
    Mo, Hongnan
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    Ma, Fei
    Xu, Binghe
    THORACIC CANCER, 2024, 15 (12) : 965 - 973
  • [49] Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2-metastatic breast cancer treated with a CDK4/6i in the first-line setting
    Behan, Emma
    Veenstra, David L.
    Bansal, Aasthaa
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (01): : 6 - 14
  • [50] CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER
    不详
    CANCER DISCOVERY, 2015, 5 (02) : 107 - 107
12345